CISPLATIIN
cis-Dichlorodiamineplatinum(II)
CAS: 15663-27-1
Molecular Formula: Cl2H6N2Pt
CISPLATIIN - Names and Identifiers
CISPLATIIN - Physico-chemical Properties
| Molecular Formula | Cl2H6N2Pt |
| Molar Mass | 300.05 |
| Density | 3,7 g/cm3 |
| Melting Point | 270 °C (lit.) |
| Solubility | Slightly soluble in water, slightly soluble in dimethylformamide. It can be gradually converted into trans and hydrolysis in aqueous solution. Water solubility <0.1g/100 mL at 19 c |
| Appearance | Orange-yellow to dark yellow solid or powder |
| Color | yellow |
| Exposure Limit | ACGIH: TWA 0.002 mg/m3NIOSH: IDLH 4 mg/m3; TWA 0.002 mg/m3 |
| Merck | 14,2317 |
| Storage Condition | 2-8°C |
| Stability | Stable. Incompatible with oxidizing agents, aluminium, antioxidants. |
| Sensitive | Sensitive to light and humidity |
| MDL | MFCD00011623 |
| Physical and Chemical Properties | Melting point 270°C water-soluble <0.1g/100 mL at 19°C |
| Use | For platinum anticancer drugs, the genitourinary system tumors and malignant pleural effusion, head and neck cancer, lung cancer and a variety of sarcomas have a significant effect on tumor radiation sensitization |
CISPLATIIN - Risk and Safety
| Hazard Symbols | T - Toxic |
| Risk Codes | R45 - May cause cancer R25 - Toxic if swallowed R41 - Risk of serious damage to eyes R60 - May impair fertility R46 - May cause heritable genetic damage R42/43 - May cause sensitization by inhalation and skin contact. R36/37/38 - Irritating to eyes, respiratory system and skin. |
| Safety Description | S53 - Avoid exposure - obtain special instructions before use. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S39 - Wear eye / face protection. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S99 - S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S22 - Do not breathe dust. |
| UN IDs | UN 3288 6.1/PG 2 |
| WGK Germany | 3 |
| RTECS | TP2455000 |
| FLUKA BRAND F CODES | 10-21 |
| TSCA | Yes |
| HS Code | 2843 90 90 |
| Hazard Class | 6.1(a) |
| Packing Group | II |
| Toxicity | LD50 in guinea pigs: 9.7 mg/kg i.p. (Fleishman) |
CISPLATIIN - Reference
| Reference Show more | 1. Zeng Tao Wen Jianhu Wang Jixiang. Study on the Mechanism of miR-148a Targeting HMGB3 to Inhibit Migration and Invasion of Non-small Cell Lung Cancer Cells and Enhance Anti-tumor Effect of Cisplatin [J]. ISTIC CA 2019, Volume 27, Issue 19, 2019. 2. Jiang Pinglin Asui Shen Yaochuan Chen Xin. Effect of Neuropilin-1 Targeted Peptide on Chemotherapy Sensitivity of Human Oral Squamous Cell Carcinoma Cell Line [J]. Southwest National Defense Medicine 2020 30(03):200-203. 3. Lu Jinlan, Xu Mengyuan, Chen Xiaofei, et al. Study on Chemical Composition and Biological Activity of Wendan Pomelo Peel Essential Oil from 6 Producing Areas in China [J]. Food Research and Development 2019 v.40;No.370(21):25-34. 4. Xu Lindi. Reversal effect and mechanism of ginseng polysaccharide on drug resistance of cisplatin-resistant human nasopharyngeal carcinoma cells [J]. World latest medical information abstract 2018 18(99):133 135. 5. Yan Haili. Pyrazolone copper complex induces BEL-7404 apoptosis of human liver cancer cells through internal and external signaling pathways [J]. Chinese Pharmacological Bulletin (04):568-576. 6. Li Zhihong, Yan Renjie, Xing Jianguo, et al. Based on serum pharmacochemistry, the active components of Xiangqinglan's anti-myocardial ischemic active site were studied [J]. Chinese Journal of Pharmaceutical Industry, 2018, v.49(08):124-130. 7. Zhong Jing, Zuo Xiaoting, Wang Xiaoqin, et al.. Study on the induction of four active ingredients of licorice [J]. Journal of Shihezi University: Natural Science Edition, 2016, 34(004):468-472. 8. Zuo Xiaoxin, Zhao Qianming, Sui Yannan, et al. Effects of Alfalfa Flavonoids on Cell Cycle and Apoptosis of Human Gastric Cancer MGC-803 [J]. Shi Zhen Guo Yi Guo Yao, 2016, 027(009):2104-2106. 9. Sun Ye, Bao Jianzhong, Liu Hong, et al. Study on Extraction and Anti-tumor Activity of Polysaccharides from Cordyceps militaris Medium [J]. Journal of Food and Biotechnology, 2019(4). 10. Zhang Lijuan, Feng Gang, Chen Wei, et al. Effects of Cisplatin on Proliferation, Cell Cycle and Hepatocellular Carcinoma Stem Cell Markers of HepG2 Cells [J]. Advances in Modern Biomedicine, 2018, v.18(11):77-81. 11. Pan Yinuo, Yang Siyang, Yu Dan, Liu Wenjun, Liu Chunying. Inhibitory Effect of Huangqi Jianzhong Decoction Combined with Cisplatin on A549 Cells and Expression of Smad3 and Smad7 [J]. Chinese Journal of Traditional Chinese Medicine, 2019,37(07):1673-1676 1815-1816. 12. Wang Xiaofang. Effects of Huangqi Jianzhong Decoction Drug-containing Serum Combined with Cisplatin on Expression of E-cadherin and Snail1 in Human Lung Adenocarcinoma A549 Cells [D]. Liaoning University of Traditional Chinese Medicine, 2020. 13. Zhou Zhan, Li Yi. Expression of ATF2 in Cervical Cancer and Effect of Silencing ATF2 to Inhibit Autophagy on Chemotherapy Sensitivity of Cervical Cancer Cells [J]. Hebei Medicine, 2021,27(02):207-211. 14. Li Jun, Zeng Qun. Effect of long-chain non-coding RNA human leukocyte antigen complex 18 on cisplatin resistance of gastric cancer cells [J]. Chinese Journal of Clinical Pharmacology, 2020,36(22):3661-3665. 15. Zhu Zhixiang, Shen Songhe, Zhao Sen, Wang Dayong, Wang Zhixue, Li Huiping. Efficacy analysis of rapamycin infusion of abdominal aorta combined with hepatic artery chemotherapy in the treatment of liver transplantation tumor rabbit model [J]. Modern Oncology Medicine, 2020,28(23):4032-4036. 16. Xia Lei, Li Mengjiao, Li Yuan, Li Xiao, Chen Qian, Nie Ke, Zhang Hairong. Effect of Pinellia ternate ginger on apoptosis of ovarian cancer SKOV3 cells [J]. Shi Zhen, Chinese Medicine, 2020,31(08):1810-1812. 17. Ji Yinghua, Yang Xiaoyu, Meng Xiangli, Wang Jin, Lu Ping. Oxymatrine reverses cisplatin resistance of cisplatin-resistant non-small cell lung cancer cells A549/Cis by down-regulating programmed cell death 1 protein expression [J]. Chinese Journal of Pharmacology and Toxicology, 2020,34(10):743-749. 18. Chen Gang. Mechanism of MicroRNA-155 Mediating Rictor/Fos Gene to Promote Cisplatin Resistance of Gastric Cancer Cells [D]. Lanzhou university, 2020. 19. Qian, Jin, et al. "Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents." European journal of pharmacology 852 (2019): 231-243.https://doi.org/10.1016/j.ejphar. 2019.04.002 20. [IF=9.867] Sun Huiying et al."CRIP1 cooperates with BRCA2 to drive the nuclear enrichment of RAD51 and to facilitate homologous repair upon DNA damage induced by chemotherapy."Oncogene. 2021 Jul;40(34):5342-5355 21. [IF=6.4] Zhiwen Cao et al."pH-Responsive Fluorescence Enhanced Nanogel for Targeted Delivery of AUR and CDDP Against Breast Cancer."Int J Nanomed. 2020; 15: 8369-8382 22. [IF=6.353] Mei Heng et al."Mitochondria-acting carrier-free nanoplatform self-assembled by α-tocopheryl succinate carrying cisplatin for combinational tumor therapy."Regen Biomater. 2021 Jun;8(4): 23. [IF=6.304] Xiong Qiao et al."Cuprous oxide nanoparticles trigger reactive oxygen species-induced apoptosis through activation of erk-dependent autophagy in bladder cancer."Cell Death Dis. 2020 May;11(5):1-13 24. [IF=5.391] Lianqiao Qiao et al."α-NETA induces pyroptosis of epithelial ovarian cancer cells through the GSDMD/caspase-4 pathway."Faseb J. 2019 Nov;33(11):12760-12767 25. [IF=4.147] An-song Liu et al."A Chemotherapy-Driven Increase in Mcl-1 Mediates the Effect of miR-375 on Cisplatin Resistance in Osteosarcoma Cells."Oncotargets Ther. 2019; 12: 11667-11677 26. [IF=4.142] Wang Huai-Song et al."Anti-cancer adjuvant drug screening via epithelial-mesenchymal transition-related aptamer probe."Anal Bioanal Chem. 2021 Nov;413(28):6951-6962 27. [IF=3.279] Pengfei Yuan et al."Cistanche tubulosa Phenylethanoid Glycosides Induce Apoptosis of Hepatocellular Carcinoma Cells by Mitochondria-Dependent and MAPK Pathways and Enhance Antitumor Effect through Combination with Cisplatin:."Integr Cancer Ther. 2021;(): 28. [IF=2.898] Zhe Deng et al."Synergistic anti-liver cancer effects of curcumin and total ginsenosides."World J Gastro Oncol. 2020 Oct 15; 12(10): 1091-1103 29. [IF=2.886] Wenli Qiu et al."Xiaoai Jiedu Recipe suppresses hepatocellular carcinogenesis through the miR‐200b-3p /Notch1 axis."Cancer Manag Res. 2020; 12: 11121-11131 30. [IF=3.989] Jingxue Zhang et al."Bevacizumab is an Efficient Therapeutic Approach with Low Side Effects in Patient-Derived Xenografts of Adenoid Cystic Carcinoma of the Lacrimal Gland."Cancer Manag Res. 2022 Mar;14:1023-1032 31. [IF=7.376] Chengtao Sun et al."Dihydrotanshinone I inhibits ovarian tumor growth by activating oxidative stress through Keap1-mediated Nrf2 ubiquitination degradation."Free Radical Bio Med. 2022 Feb;180:220 32. [IF=4.384] Qianwen Li et al."Estrone-targeted PEGylated Liposomal Nanoparticles for Cisplatin (DDP) Delivery in Cervical Cancer."EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2022 Jul;174:106187 33. [IF=4.412] Feng Su et al."Study of Chemical Compositions and Anticancer Effects of Paris polyphylla var. Chinensis Leaves."MOLECULES. 2022 Jan;27(9):2724 |
CISPLATIIN - Standard
Authoritative Data Verified Data
This product is (Z)-platinum diamine dichloride. The content of Cl2H6N2Pt shall be between 98.0% and 102.0% based on the dry product.
Last Update：2024-01-02 23:10:35
CISPLATIIN - Trait
Authoritative Data Verified Data
- This product is a crystalline powder of bright yellow to orange yellow; Odorless.
- This product is soluble in dimethyl sulfoxide, slightly soluble in N ,N-dimethylformamide, slightly soluble in water, insoluble in ethanol.
Last Update：2022-01-01 14:18:36
CISPLATIIN - Introduction
Slightly soluble in water, easily soluble in dimethylformamide. It can be gradually converted into trans and hydrolysis in aqueous solution.
Last Update：2022-10-16 17:14:11
CISPLATIIN - Differential diagnosis
Authoritative Data Verified Data
- take about 5mg of this product, and add 1 ml sulfuric acid, it will appear gray-green.
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
- take this product, add 0.9% sodium chloride solution to make a solution containing about 1 mg per 1 ml, according to UV-visible spectrophotometry (General 0401) determination, there is a maximum absorption at a wavelength of 301nm and a minimum absorption at a wavelength of 247nm.
- The infrared absorption spectrum of this product should be consistent with that of the control (Spectrum set 297).
Last Update：2022-01-01 14:18:37
CISPLATIIN - Exam
Authoritative Data Verified Data
platinum content
take about 0.5g of this product, weigh it precisely, and burn it to constant weight at 0841 ° C according to the method of burning residue inspection (General Rule 400, but without sulfuric acid), the weight of the residue obtained is the weight of the drill contained in the Test amount. Based on the dry product, the platinum content should be 64.6% ~ 65.4%.
chlorine content
take this product 30mg, precision weighing, according to the oxygen flask combustion method (General rule 0703) for organic destruction, with sodium hydroxide solution 20ml as the absorption liquid, once the combustion is completed, shake strongly for several minutes, rinse the bottle stopper and silk with a small amount of water, add 1 drop of bromophenol blue indicator solution to the liquid, add dilute nitric acid Dropwise until the solution turns yellow, then add 1ml of dilute nitric acid, 5 drops of 20ml ethanol and 1% diphenylhydrazine ethanol solution were titrated with mercury nitrate titration solution (0.025mol/L), with strong shaking near the end point, titration was continued until the solution was Pale Rose Red and the results of the titration were corrected with a blank test. Each 1ml of mercury nitrate titration solution (0.025mol/L) is equivalent to 23.0% mg of chlorine (C1), and the chlorine content should be 24.3%.
clarity of the solution
Take 20mg of this product, add 20ml of 0.9% sodium chloride solution to dissolve, the solution should be clarified.
acidity
take the solution under the clarity of the solution, measured by law (General 0631), the pH value should be 5.0~7.0.
Related substances
operation in the dark. Take this product, add 0.9% sodium chloride solution to dissolve and dilute to make a solution containing about 0.2mg per lml as a test solution (ready to use new system); Take 1ml for precision measurement and put it in a 50ml measuring flask, as a control solution, it was diluted to the mark with 0.9% sodium chloride solution and shaken. According to the chromatographic conditions under the content determination item, 20ul of each of the test solution and the control solution are accurately measured and injected into the liquid chromatograph respectively, and the chromatogram is recorded to 2 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the area of the impurity peak with a relative retention time of about 0.87 multiplied by 0.569 shall not be greater than 0.5 times (1.0%) of the area of the main peak of the control solution, the Peak area of impurities with relative retention time of about 1.2 multiplied by 1.356 shall not be greater than the main peak area of the control solution (2.0%), and the sum of other impurity peak areas shall not be greater than 0.25 times the main peak area of the control solution (0.5%).
loss on drying
take about O.lg of this product, dry to constant weight at 105°C, and lose no more than 0.5% of weight (General rule 0831).
Last Update：2022-01-01 14:18:38
CISPLATIIN - Content determination
Authoritative Data Verified Data
measured by high performance liquid chromatography (General 0512).
chromatographic conditions and system suitability test
silica gel bonded with eighteen alkyl silane was used as the filler; 0.003mol/L sodium heptane sulfonate 0.9% sodium chloride solution was used as the mobile phase; The detection wavelength was 220nm. The number of theoretical plates shall not be less than 3000 calculated by cisplatin peak, and the separation degree between cisplatin peak and adjacent impurity peaks shall meet the requirements.
assay
operation in the dark. Take an appropriate amount of this product, precision weighing, add 0.9% sodium chloride solution to dissolve and quantitatively dilute to make a solution containing about 40ug per lml, as a test solution, take 20u1 injection of human liquid chromatograph for precision measurement, the chromatogram was recorded; Another reference substance of cisplatin was taken and determined by the same method. According to the external standard method to calculate the peak area, that is.
Last Update：2022-01-01 14:18:38
CISPLATIIN - Category
Authoritative Data Verified Data
antineoplastic agents.
Last Update：2022-01-01 14:18:38
CISPLATIIN - Storage
Authoritative Data Verified Data
light shielding, sealed storage.
Last Update：2022-01-01 14:18:39
CISPLATIIN - Cisplatin for injection
Authoritative Data Verified Data
This product is sterile powder or sterile lyophilized product of cisplatin. Cisplatin (Cl2H6N2Pt) should be contained in 90.0% to 110.0% of the labeled amount based on the average loading.
trait
This product is a crystalline powder from bright yellow to orange yellow, or a yellowish to yellow loose mass or powder.
identification
take this product, according to the identification test under the item of cisplatin [if it is sterile lyophilized product, identification items except (4), show the same results.
examination
- the acidity and loss on drying shall be checked according to the method in accordance with the item, and shall be in accordance with the regulations.
- the related substances were protected from light. Take this product, add 0.9% sodium chloride solution to dissolve and dilute the solution containing about mg of cisplatin in each lml as the test solution; Determine according to the method under the item of cisplatin related substances. If there are impurity peaks in the chromatogram of the test solution, the peak area of the impurity peak with relative retention time of about 0.87 multiplied by 0.569 shall not be greater than 0.5 times (1.0%) of the main peak area of the control solution, the relative retention time was about 1 .2 The Peak area of the impurity peak multiplied by 1.356 shall not be greater than the main peak area of the control solution (2.0%), and the sum of other impurity peak areas shall not be greater than 0.5 times (1.0%) of the main peak area of the control solution.
- bacterial endotoxin this product, according to the law to check (General 1143), each 1 mg of cisplatin containing endotoxin should be less than 1.7EU.
- others should comply with the relevant provisions under injection (General 0102).
Content determination
take the appropriate amount of contents under the item of difference in loading amount, weigh it precisely, add 0.9% sodium chloride solution to dissolve the cisplatin and quantitatively dilute it to make a solution containing about 40ug of cisplatin per 1 ml, as a test solution, it was obtained by measuring according to the method under the item of measuring the content of cisplatin.
category
Same as cisplatin.
specification
(l)10mg (2)20mg (3)30mg
storage
light shielding, closed storage.
Last Update：2022-01-01 14:18:39
CISPLATIIN - Reference Information
| (IARC) carcinogen classification | 2A (vol. 26, sup 7) 1987, 1 (vol. 76, 100a) 2012 |
| EPA chemical information | Information provided by: ofmpub.epa.gov (external link) |
| Discovery history | Cisplatin is one of the most commonly used drugs in current combination chemotherapy. The full chemical name is cis-dichlorodiammine platinum, which is an inorganic metal complex. After dissociating chlorine, it is cross-linked with the DNA of cancer cells, thereby destroying DNA function. It may form intra-chain or inter-chain cross-links with DNA, and may also form cross-links with DNA and proteins, and inhibit cell mitosis. It is a cell cycle non-specific drug. In addition to anti-cancer, it can also inhibit lymphocyte transformation. It has immunosuppressive effect and can be used as a metal complex of anti-cancer drugs. It was first made by the French chemist Pieronny in 1844 and was once called Pieronny's salt. An orange-yellow crystal with very small solubility (0.252g/100g water at 25 ℃), which can be prepared by reacting potassium tetrachloroplatinum (II) solution with ammonia water. In 1891, Werner, the founder of modern coordination chemistry, established the coordination theory from the study of this type of compound, and clarified the cis structure of Pillonite salt. The anticancer activity of cisplatin was not discovered by Rosenberg and his colleagues at the University of Michigan until 1965. When they studied the effect of electric field on the growth of E. coli, they found that the reproduction of E. coli was inhibited after putting a metal platinum electrode in the culture solution containing ammonium chloride and then passing a current of 2 amperes for two hours. Further studies have shown that this is due to the effect of cisplatin, the product of the chemical reaction between platinum ions and ammonium chloride solution, produced by electrolytic oxidation of trace platinum on the electrode. Rosenberg believes that since cisplatin can prevent cell division, it should have anti-cancer activity. Through anti-cancer tests, it has been proved that cisplatin has a good anti-cancer effect, which has aroused people's interest in metal complex pharmacology, organized international cooperative research in chemistry, biology, and medicine, and finally made cisplatin in the treatment of cancer Successful application. In December 1978, the U.S. Food and Drug Administration approved the use of cisplatin for clinical use and as a commercial supply market. It has the characteristics of broad anti-tumor spectrum and effective against hypoxic cells. But it is toxic to the kidneys, nervous system and pancreas. Modern pharmacology classifies this product as an anti-tumor drug. |
| pharmacological effects | cisplatin, also known as cisplatin, cisplatin, DDP, tin platinum, ethaplatin, cisplatin-dichlorodiaminoplatin, is currently commonly used metal platinum complexes, and platinum atoms in the molecule have important significance for its anti-tumor effects. But only cis makes sense, and trans is invalid. It can be cross-linked with DNA strands, showing cytotoxic effects. After dissolution, it can pass through charged cell membranes in the body without carrier transport. Due to the low concentration of chloride ions in the cell (4mmol/L), the chloride ions are replaced by water, and the charge is positive. It has the effect of an alkylating agent bifunctional group, which can bind to the bases of DNA in the nucleus to form three forms of cross-linking, causing DNA damage, destroying DNA replication and transcription, and inhibiting RNA and protein synthesis at high concentrations. Cisplatin has the advantages of broad anti-cancer spectrum, effective hypoxic cells, and strong action. It has been widely used in the treatment of testicular cancer, ovarian cancer, uterine cancer, bladder cancer, neck cancer, prostate cancer, brain cancer, etc., with significant effects. However, cisplatin is used to treat cancer with certain toxicity and can cause side effects. Therefore, it is necessary to continuously look for analogs with less toxicity and similar clinical effects to cisplatin. So far, scientists from various countries have synthesized and tested thousands of metal complexes related to cisplatin, and developed the second generation of anti-cancer platinum complexes represented by carbon platinum. The third generation of anticancer metal complexes have also been discovered, represented by titanium dichlorocene. These compounds have nothing to do with cisplatin from a chemical point of view, but they have a good effect on some carcinomas with little cisplatin treatment effect, and do not harm renal function. At present, a lot of research is still going on in this field, focusing on exploring the mechanism of anti-cancer activity of metal complexes at the molecular level. China has produced commercial cisplatin and carried out research work in this area. Cisplatin is a non-specific drug of the cell cycle and has cytotoxicity. Because cancer cells proliferate and synthesize more rapidly than normal cells, cancer cells are more sensitive to the cytotoxic effect of this product, which can inhibit the DNA replication process of cancer cells and damage the structure of their cell membranes. It has a strong broad-spectrum anti-cancer effect. It is used for malignant tumors of the genitourinary system such as ovarian cancer, prostate cancer, and testicular cancer, and has a good effect. Combined with vincristine, cyclophosphamide, 5-fluorouracil, it can be effective for malignant lymphoma, breast cancer, head and neck squamous cell carcinoma, thyroid carcinoma osteosarcoma, etc. Cisplatin combined with radiotherapy is effective in the treatment of advanced non-small cell lung cancer, nasopharyngeal cancer, esophageal cancer, etc. It also has a certain effect on liver cancer and soft tissue sarcoma. Cisplatin is a strong accumulative drug, which is prone to nephrotoxicity. Gastrointestinal reactions are more common. Some patients have neutropenia, but it can recover within 7 to 14 days after stopping the drug. In addition, the damage of this product to DNA may also change its antigenicity in the nucleus or cell surface, expose the original hidden surface antigen, stimulate the immunosuppression of antibodies and exert its cytotoxic effect. |
| clinical application | cisplatin (cisplatin,CDDP) can be said to be a veritable "old" drug, synthesized by m Peyrone as early as 1845, so it is also called Peyrone salt. Cisplatin entered clinical trials in 1971, the patent of cisplatin was transferred to Squibb in 1977, and was approved for clinical application by the U.S. Food and Drug Administration (FDA) in 1978. It is still one of the platinum anticancer drugs widely used in clinic. The cure rate of testicular cancer is almost 100%, and it also has a good effect on malignant tumors such as ovarian cancer, lung cancer, head and neck cancer, and bone cancer. Therefore, it is also known as "penicillin in anti-cancer drugs". Cisplatin (DDP) has the characteristics of broad anti-cancer spectrum, strong effect, synergistic effect with a variety of anti-tumor drugs, and no cross-resistance. It is one of the most commonly used drugs in current combined chemotherapy. (1) Reproductive system tumors: It is effective for ovarian cancer and testicular cancer. The combined chemotherapy of DDP and ADM can make more than 40% ovarian cancer achieve better curative effect. The effective rate and cure rate of DDP combined with BLM and VLB for non-spermatogonogenic testicular cancer reach 80% and 60% respectively. It can also be used for choriocarcinoma, cervical cancer and other reproductive system tumors. (2) Head and neck cancer: nasopharyngeal carcinoma, thyroid cancer, laryngeal cancer, etc. (3) It also has certain curative effect on bladder cancer, lung cancer, malignant lymphoma, breast cancer, renal cell carcinoma, prostate cancer, soft tissue sarcoma and malignant melanoma. (4) Others: malignant pleural and ascites; combined with radiotherapy, it has radiosensitization effect. |
| adverse reactions and side effects | once cisplatin was injected at 50mg/m2, azotemia occurred in 25% ~ 30% patients. Larger doses and continuous medication can produce severe and long-lasting renal toxicity, manifested as renal tubular swelling, degenerative disease, increased serum urea ammonia, decreased creatinine clearance, hematuria, proteinuria, and even uremia. There may be mild to moderate bone marrow toxicity, the degree of which depends on the dosage of cisplatin. Anemia is common and may have hemolytic effect. Severe nausea and vomiting may occur within 1 hour of starting medication for 8~12 hours. Dexamethasone, ondansetron and diazepam can be used to reduce the reaction. malignant nephrotoxic reaction can occur, which is easy to occur in those who have not been treated with hydration and diuresis. Combined with nephrotoxic antibiotics can increase the risk of acute renal failure. Common high-frequency hearing loss, occasionally obvious hearing loss, rare tinnitus. There may be obvious low sodium, low magnesium, low calcium, hypokalemia, which may occur a few days after treatment. Allergic reactions can occur after several times of medication, which occur within a few minutes after administration, manifested as facial edema, wheezing, tachycardia, etc., anti-histamine drugs, adrenal cortex hormones and other anti-allergic measures should be given quickly. peripheral neurotoxic reactions may occur. Rare hyperuricemia. Occasionally symptomatic orthostatic hypotension. |
| drug interaction | (1) combined with aminoglycoside antibacterial drugs, amphotericin B or cefalotin, etc., with nephrotoxicity superimposed effect. (2) Methotrexate and bleomycin are mainly excreted by kidney. The renal damage caused by this product will delay the excretion of the above two drugs, resulting in increased renal toxicity. (3) combined with probenecid can cause hyperuricemia. (4) combined with chloramphenicol, furosemide or etanoic acid can increase the ototoxicity of this product. (5) anti-group femoral drugs can cover up tinnitus, vertigo and other symptoms caused by this product. |
| Use | This product can bind to DNA and cause cross-connections, thereby destroying DNA function and inhibiting cell mitosis. It is a cell non-specific drug. The product has a wide anti-tumor spectrum and is used for head and neck squamous cell carcinoma, ovarian cancer, embryonic cell carcinoma, seminoma, lung cancer, thyroid cancer, lymphosarcoma and reticulosarcoma. it is a platinum anticancer drug, which has significant curative effect on genitourinary system tumors, cancerous pleural effusion, head and neck cancer, lung cancer and various sarcomas, and has sensitizing effect on tumor radiation it is a highly effective platinum-based anticancer drug, which is inserted into DNA d(pGpG) interval to cross-link the internal chain. Medically used as a highly active chemotherapy substance to prevent the spread of testicular cancer. |
| production method | is prepared by complexing potassium tetrachloroplatinate with ammonium chloride and ammonia. |
| toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |
Last Update：2024-04-09 21:21:28
Supplier List
Multiple SpecificationsSpot supply
Product Name: Cis-Diammineplatinum dichloride Visit Supplier Webpage Request for quotationCAS: 15663-27-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Multiple SpecificationsSpot supply
Product Name: Cis-Diammineplatinum dichloride Visit Supplier Webpage Request for quotationCAS: 15663-27-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History